CA2742242C - Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody - Google Patents
Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody Download PDFInfo
- Publication number
- CA2742242C CA2742242C CA2742242A CA2742242A CA2742242C CA 2742242 C CA2742242 C CA 2742242C CA 2742242 A CA2742242 A CA 2742242A CA 2742242 A CA2742242 A CA 2742242A CA 2742242 C CA2742242 C CA 2742242C
- Authority
- CA
- Canada
- Prior art keywords
- single chain
- pediatric
- chain antibody
- bispecific single
- cd19xcd3 bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US61/112,323 | 2008-11-07 | ||
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US61/183,291 | 2009-06-02 | ||
| US22126909P | 2009-06-29 | 2009-06-29 | |
| US61/221,269 | 2009-06-29 | ||
| PCT/EP2009/007969 WO2010052013A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2742242A1 CA2742242A1 (en) | 2010-05-14 |
| CA2742242C true CA2742242C (en) | 2023-01-10 |
Family
ID=41796119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2742242A Active CA2742242C (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20110262440A1 (https=) |
| EP (4) | EP2344539B1 (https=) |
| JP (2) | JP5798036B2 (https=) |
| KR (1) | KR101695329B1 (https=) |
| CN (2) | CN102209729B (https=) |
| AU (1) | AU2009313039B2 (https=) |
| BR (1) | BRPI0921341A2 (https=) |
| CA (1) | CA2742242C (https=) |
| CY (3) | CY1116160T1 (https=) |
| DK (3) | DK2918604T3 (https=) |
| ES (3) | ES2748126T3 (https=) |
| HK (1) | HK1255590B (https=) |
| HR (3) | HRP20150400T1 (https=) |
| HU (3) | HUE046222T2 (https=) |
| IL (1) | IL212651A (https=) |
| LT (2) | LT3330293T (https=) |
| MX (1) | MX2011002931A (https=) |
| NO (1) | NO2918604T3 (https=) |
| NZ (1) | NZ591312A (https=) |
| PL (3) | PL2918604T3 (https=) |
| PT (3) | PT3330293T (https=) |
| RS (3) | RS59348B1 (https=) |
| RU (3) | RU2536933C2 (https=) |
| SG (1) | SG195549A1 (https=) |
| SI (3) | SI2344539T1 (https=) |
| SM (3) | SMT201900546T1 (https=) |
| WO (1) | WO2010052013A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| PT3330293T (pt) * | 2008-11-07 | 2019-10-18 | Amgen Res Munich Gmbh | Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19 |
| EP2386062B1 (en) * | 2009-01-09 | 2016-01-06 | Oxford Biomedica (UK) Ltd | Factors |
| US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014075788A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN103131777A (zh) * | 2013-02-05 | 2013-06-05 | 南京艾迪康医学检验所有限公司 | 用于检测e2a-pbx融合基因相对表达量的试剂盒 |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2715679T3 (es) | 2014-05-30 | 2019-06-05 | Amgen Res Munich Gmbh | Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B |
| US20170252364A1 (en) * | 2014-07-30 | 2017-09-07 | Mor Research Applications Ltd. | Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof |
| WO2016061368A1 (en) * | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| HK1250146A1 (zh) | 2015-02-05 | 2018-11-30 | Stc.Unm | 抗前-bcr拮抗剂和方法 |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| RS66511B1 (sr) | 2015-05-20 | 2025-03-31 | Amgen Res Munich Gmbh | Deplecija b ćelija kao dijagnostički marker |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| AU2016378573A1 (en) * | 2015-12-22 | 2018-07-19 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| IL261750B2 (en) * | 2016-03-14 | 2024-07-01 | Millennium Pharm Inc | Method of preventing graft versus host disease |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| MX2019013142A (es) * | 2017-05-05 | 2019-12-16 | Amgen Inc | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| WO2020160310A1 (en) * | 2019-01-30 | 2020-08-06 | The Wistar Institute Of Anatomy And Biology | Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12285494B2 (en) | 2021-02-16 | 2025-04-29 | Children's Health Care | Methods for treating B-ALL by administering a pre-BCR complex antagonist |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| US20250282864A1 (en) | 2021-10-15 | 2025-09-11 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engagers |
| US20250146017A1 (en) | 2023-11-06 | 2025-05-08 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025250648A1 (en) * | 2024-05-28 | 2025-12-04 | Ohio State Innovation Foundation | Methods and compositions comprising tagless blinatumomab |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4119397A (en) * | 1996-08-28 | 1998-03-19 | Viva Diagnostika Diagnostische Produkte Gmbh | Novel combination preparations and their use in immunodiagnosis and immunotherapy |
| CZ302070B6 (cs) * | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| DE602004030811D1 (de) * | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| DK1976886T3 (en) | 2005-12-16 | 2015-03-02 | Amgen Res Munich Gmbh | Means and methods for the treatment of tumor diseases |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| PL2352763T5 (pl) * | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| PT3330293T (pt) * | 2008-11-07 | 2019-10-18 | Amgen Res Munich Gmbh | Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19 |
| CN102282128B (zh) * | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| CN102282129A (zh) * | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| MX2011012632A (es) * | 2009-05-27 | 2012-03-06 | Abbott Lab | Inhibidores de actividad de cinasa tipo pirimidina. |
| BR112012006252A2 (pt) * | 2009-09-20 | 2017-05-23 | Abbott Lab | "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2". |
| CN107227335A (zh) * | 2009-10-27 | 2017-10-03 | 安进研发（慕尼黑）股份有限公司 | 用于施用CD19xCD3双特异性抗体的给药方案 |
-
2009
- 2009-11-06 PT PT172068686T patent/PT3330293T/pt unknown
- 2009-11-06 RS RSP20191232 patent/RS59348B1/sr unknown
- 2009-11-06 EP EP09764710.1A patent/EP2344539B1/en active Active
- 2009-11-06 SI SI200931185T patent/SI2344539T1/sl unknown
- 2009-11-06 NO NO15154416A patent/NO2918604T3/no unknown
- 2009-11-06 SM SM20190546T patent/SMT201900546T1/it unknown
- 2009-11-06 EP EP17206868.6A patent/EP3330293B1/en active Active
- 2009-11-06 ES ES17206868T patent/ES2748126T3/es active Active
- 2009-11-06 HU HUE17206868A patent/HUE046222T2/hu unknown
- 2009-11-06 PT PT97647101T patent/PT2344539E/pt unknown
- 2009-11-06 KR KR1020117010642A patent/KR101695329B1/ko active Active
- 2009-11-06 DK DK15154416.0T patent/DK2918604T3/en active
- 2009-11-06 LT LTEP17206868.6T patent/LT3330293T/lt unknown
- 2009-11-06 JP JP2011533632A patent/JP5798036B2/ja active Active
- 2009-11-06 PL PL15154416T patent/PL2918604T3/pl unknown
- 2009-11-06 AU AU2009313039A patent/AU2009313039B2/en active Active
- 2009-11-06 WO PCT/EP2009/007969 patent/WO2010052013A1/en not_active Ceased
- 2009-11-06 HU HUE09764710A patent/HUE025452T2/en unknown
- 2009-11-06 CN CN200980144400.7A patent/CN102209729B/zh active Active
- 2009-11-06 DK DK09764710.1T patent/DK2344539T3/en active
- 2009-11-06 SM SM20180149T patent/SMT201800149T1/it unknown
- 2009-11-06 NZ NZ591312A patent/NZ591312A/xx unknown
- 2009-11-06 US US13/127,538 patent/US20110262440A1/en not_active Abandoned
- 2009-11-06 EP EP15154416.0A patent/EP2918604B1/en active Active
- 2009-11-06 SI SI200931995T patent/SI3330293T1/sl unknown
- 2009-11-06 PL PL17206868T patent/PL3330293T3/pl unknown
- 2009-11-06 PT PT151544160T patent/PT2918604T/pt unknown
- 2009-11-06 PL PL09764710T patent/PL2344539T3/pl unknown
- 2009-11-06 LT LTEP15154416.0T patent/LT2918604T/lt unknown
- 2009-11-06 BR BRPI0921341A patent/BRPI0921341A2/pt not_active Application Discontinuation
- 2009-11-06 RS RS20180309A patent/RS56989B1/sr unknown
- 2009-11-06 SG SG2013076310A patent/SG195549A1/en unknown
- 2009-11-06 SI SI200931817T patent/SI2918604T1/en unknown
- 2009-11-06 CA CA2742242A patent/CA2742242C/en active Active
- 2009-11-06 EP EP19187179.7A patent/EP3594237A1/en active Pending
- 2009-11-06 CN CN201610281293.4A patent/CN106390114A/zh active Pending
- 2009-11-06 DK DK17206868.6T patent/DK3330293T3/da active
- 2009-11-06 HU HUE15154416A patent/HUE036922T2/hu unknown
- 2009-11-06 ES ES09764710.1T patent/ES2535257T3/es active Active
- 2009-11-06 HR HRP20150400TT patent/HRP20150400T1/hr unknown
- 2009-11-06 ES ES15154416.0T patent/ES2662929T3/es active Active
- 2009-11-06 RU RU2011122827/10A patent/RU2536933C2/ru active
- 2009-11-06 RS RS20150306A patent/RS53980B1/sr unknown
- 2009-11-06 MX MX2011002931A patent/MX2011002931A/es active IP Right Grant
-
2011
- 2011-05-03 IL IL212651A patent/IL212651A/en active IP Right Grant
-
2014
- 2014-10-13 RU RU2014141180A patent/RU2677324C2/ru active
-
2015
- 2015-03-31 CY CY20151100317T patent/CY1116160T1/el unknown
- 2015-04-27 SM SM201500104T patent/SMT201500104B/xx unknown
- 2015-08-20 JP JP2015163116A patent/JP6130451B2/ja active Active
-
2018
- 2018-03-12 HR HRP20180426TT patent/HRP20180426T1/hr unknown
- 2018-03-14 CY CY20181100310T patent/CY1120022T1/el unknown
- 2018-11-16 HK HK18114719.1A patent/HK1255590B/en unknown
- 2018-12-14 RU RU2018144313A patent/RU2736802C2/ru active
-
2019
- 2019-09-20 HR HRP20191715 patent/HRP20191715T1/hr unknown
- 2019-10-03 CY CY20191101035T patent/CY1122428T1/el unknown
-
2022
- 2022-09-16 US US17/932,739 patent/US20230235053A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230235053A1 (en) | Treatment of pediatric acute lymphoblastic leukemia | |
| HK1255590A1 (en) | Treatment of pediatric acute lymphoblastic leukemia with bispecific antibodies against cd3xcd19 | |
| US20240109964A1 (en) | Treatment of acute lymphoblastic leukemia | |
| HK40022438A (en) | Treatment of pediatric acute lymphoblastic leukemia | |
| HK1215258B (en) | Treatment of pediatric acute lymphoblastic leukemia | |
| HK1158667B (en) | Treatment of pediatric acute lymphoblastic leukemia | |
| HK1220705B (en) | Treatment of acute lymphoblastic leukemia | |
| HK1158668B (en) | Treatment of acute lymphoblastic leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141024 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241024 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241024 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |